Simplex Trading’s VYNE Therapeutics VYNE Stock Holding History

Simplex Trading’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1	Closed	–	–	10565
2022 Q3	$0	Sell	1 -4	-80%	-$26	﹤0.01%	10989
2022 Q2	$0	Buy	+5	New	+$42	﹤0.01%	11225
2022 Q1	–	Sell	-109	Closed	-$1.29K	–	11497
2021 Q4	$2K	Buy	+109	New	+$2.34K	﹤0.01%	10075
2021 Q2	–	Sell	-400	Closed	-$31.7K	–	10778
2021 Q1	$49K	Buy	+400	New	+$58K	﹤0.01%	6653

Other funds holding VYNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return

CAN

Cetera Advisor Networks El Segundo, California $20.2B AUM 22.31% 1-Year Est. Return

Simplex Trading's VYNE Position: Q4 2022 in Review

Simplex Trading sold out of VYNE Therapeutics (VYNE) in Q4 2022, closing a stake of 1 share.

Simplex Trading first reported a position in VYNE in Q1 2021 and held it in 4 quarters. The position peaked at $49K in Q1 2021. 41 funds tracked by Wall St. Rank hold VYNE as of Q4 2022.

Simplex Trading reported no remaining VYNE Therapeutics position as of Q4 2022 after selling out during the quarter.
Simplex Trading sold 1 VYNE Therapeutics share in Q4 2022.
Simplex Trading first reported a position in VYNE Therapeutics in Q1 2021 and held it in 4 quarters.
Simplex Trading's VYNE Therapeutics position peaked at $49K in Q1 2021.
41 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2022.

Based on Simplex Trading's 13F filing for Q4 2022, filed 2 Feb 2023.